Combined wIRA-Hyperthermia and Hypofractionated Re-Irradiation in the Treatment of Locally Recurrent Breast Cancer: Evaluation of Therapeutic Outcome Based on a Novel Size Classification.

LRBC clinical outcome locally recurrent breast cancer novel size classification re-irradiation superficial hyperthermia toxicity wIRA hyperthermia

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
06 Mar 2020
Historique:
received: 24 01 2020
revised: 02 03 2020
accepted: 03 03 2020
entrez: 12 3 2020
pubmed: 12 3 2020
medline: 12 3 2020
Statut: epublish

Résumé

Effective tumor control in patients suffering from unresectable locally recurrent breast cancer (LRBC) in pre-irradiated areas can be achieved by re-irradiation combined with superficial hyperthermia. Using this combined modality, total re-irradiation dose and toxicity can be significantly reduced compared to conventionally fractionated treatment schedules with total doses of 60-66 Gy. Applying contact-free, thermography-controlled water-filtered infrared-A superficial hyperthermia, immediately followed by hypofractionated re-irradiation, consisting of 4 Gy once per week up to a total dose of 20 Gy, resulted in high overall response rates even in large-sized tumors. Comparability of clinical data between different combined Hyperthermia (HT)/Radiotherapy (RT) treatment schedules is impeded by the highly individual characteristics of this disease. Tumor size, ranging from microscopic disease and small lesions to large-sized cancer en cuirasse, is described as one of the most important prognostic factors. However, in clinical studies and analyses of LRBC, tumor size has so far been reported in a very heterogeneous way. Therefore, we suggest a novel, simple and feasible size classification (rClasses 0-IV). Applying this classification for the evaluation of 201 patients with pre-irradiated LRBC allowed for a stratification into distinct prognostic groups.

Identifiants

pubmed: 32155740
pii: cancers12030606
doi: 10.3390/cancers12030606
pmc: PMC7139693
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Int J Hyperthermia. 2012;28(6):528-42
pubmed: 22690925
Int J Hyperthermia. 2019;36(1):986-992
pubmed: 31544546
Clin Oncol (R Coll Radiol). 2018 Feb;30(2):73-84
pubmed: 29224899
Radiother Oncol. 2015 Nov;117(2):223-8
pubmed: 26542015
Breast. 2017 Jun;33:159-165
pubmed: 28395234
Radiat Oncol. 2017 Apr 27;12(1):75
pubmed: 28449703
Wien Med Wochenschr. 2002;152(13-14):334-42
pubmed: 12168517
Int J Hyperthermia. 2018;35(1):26-36
pubmed: 29745269
J Natl Compr Canc Netw. 2007 Mar;5(3):345-8
pubmed: 17439763
Clin Breast Cancer. 2017 Nov;17(7):493-502
pubmed: 28396099
Cancers (Basel). 2019 Jun 05;11(6):
pubmed: 31195763
Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):365-75
pubmed: 9457823
Int J Hyperthermia. 2017 Mar;33(2):227-236
pubmed: 27618745
Antioxid Redox Signal. 2007 Aug;9(8):1221-35
pubmed: 17536958
Clin Oncol (R Coll Radiol). 2007 Aug;19(6):418-26
pubmed: 17493790
Strahlenther Onkol. 2019 Apr;195(4):318-326
pubmed: 30607453
Int J Hyperthermia. 2005 Dec;21(8):779-90
pubmed: 16338861
Radiat Oncol. 2015 Sep 17;10:197
pubmed: 26383236
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1073-87
pubmed: 26899950
Adv Drug Deliv Rev. 2020 Jan 23;:
pubmed: 31982475
Radiother Oncol. 2013 Nov;109(2):188-93
pubmed: 23742962
Oncotarget. 2015 Oct 27;6(33):35051-62
pubmed: 26459388
Int J Radiat Oncol Biol Phys. 1980 Nov;6(11):1507-17
pubmed: 7462053
Strahlenther Onkol. 2018 Mar;194(3):206-214
pubmed: 29264624
Cancers (Basel). 2019 Jan 09;11(1):
pubmed: 30634444

Auteurs

Markus Notter (M)

Department of Radiation Oncology, Lindenhofspital Bern, 3012 Bern, Switzerland.

Andreas R Thomsen (AR)

Department of Radiation Oncology, Medical Center, University of Freiburg, 79106 Freiburg, Germany.
German Cancer Consortium (DKTK), Partner Site Freiburg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Mirko Nitsche (M)

Center for Radiotherapy and Radiooncology Bremen and Westerstede, 28239 Bremen, Germany.

Robert M Hermann (RM)

Center for Radiotherapy and Radiooncology Bremen and Westerstede, 28239 Bremen, Germany.

Hendrik A Wolff (HA)

Department of Radiology, Nuclear Medicine and Radiotherapy, Radiology Munich, 80333 Munich, Germany.
Department of Radiation Oncology, Medical Center, University of Regensburg, 93053 Regensburg, Germany.

Gregor Habl (G)

Department of Radiology, Nuclear Medicine and Radiotherapy, Radiology Munich, 80333 Munich, Germany.
Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany.

Karin Münch (K)

Department of Radiation Oncology, Lindenhofspital Bern, 3012 Bern, Switzerland.

Anca-L Grosu (AL)

Department of Radiation Oncology, Medical Center, University of Freiburg, 79106 Freiburg, Germany.
German Cancer Consortium (DKTK), Partner Site Freiburg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Peter Vaupel (P)

Department of Radiation Oncology, Medical Center, University of Freiburg, 79106 Freiburg, Germany.
German Cancer Consortium (DKTK), Partner Site Freiburg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Classifications MeSH